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Abstract
Medulloblastoma (MB) is the most common malignant brain tumor in children and a leading cause of cancer-related
mortality and morbidity. Several molecular sub-types of MB have been identified, suggesting they may arise from distinct
cells of origin. Data from animal models indicate that some MB sub-types arise from multipotent cerebellar neural stem cells
(NSCs). Hence, microRNA (miRNA) expression profiles of primary MB samples were compared to CD133+ NSCs, aiming to
identify deregulated miRNAs involved in MB pathogenesis. Expression profiling of 662 miRNAs in primary MB specimens, MB
cell lines, and human CD133+ NSCs and CD1332 neural progenitor cells was performed by qRT-PCR. Clustering analysis
identified two distinct sub-types of MB primary specimens, reminiscent of sub-types obtained from their mRNA profiles. 21
significantly up-regulated and 12 significantly down-regulated miRNAs were identified in MB primary specimens relative to
CD133+ NSCs (p,0.01). The majority of up-regulated miRNAs mapped to chromosomal regions 14q32 and 17q. Integration
of the predicted targets of deregulated miRNAs with mRNA expression data from the same specimens revealed enrichment
of pathways regulating neuronal migration, nervous system development and cell proliferation. Transient over-expression
of a down-regulated miRNA, miR-935, resulted in significant down-regulation of three of the seven predicted miR-935 target
genes at the mRNA level in a MB cell line, confirming the validity of this approach. This study represents the first integrated
analysis of MB miRNA and mRNA expression profiles and is the first to compare MB miRNA expression profiles to those of
CD133+ NSCs. We identified several differentially expressed miRNAs that potentially target networks of genes and signaling
pathways that may be involved in the transformation of normal NSCs to brain tumor stem cells. Based on this integrative
approach, our data provide an important platform for future investigations aimed at characterizing the role of specific
miRNAs in MB pathogenesis.
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Introduction
Medulloblastoma (MB) is the most common malignant pediatric
brain tumor, with an incidence of approximately 0.5 per 100 000
children less than 15 years of age [1]. Current multi-modal
treatment consists of surgery, radiation and adjuvant chemother-
apy [2,3]. Although recent advances in therapy have lifted five-
year survival rates for average-risk MB to 80%, the outcome for
high-risk patients remains poor [4,5]. Additionally, the long term
consequences of existing treatment protocols can be profound and
include both intellectual and developmental impairment [6].
Clearly, less invasive and more effective treatment strategies for
MB are urgently required.
MB is a heterogeneous disease and current risk stratification
strategies often fail to accurately predict disease outcome.
Recent microarray gene expression studies and genomic analyses
have contributed to the improved sub-classification of MB,
incorporating clinical and demographic characteristics to identify
at least four distinct sub-types according to their specific gene
expression signatures [7–10]. Sub-types A and B are characterized
by over-active Wingless-type MMTV integration site family (Wnt)
and Hedgehog (Hh) signaling respectively, while sub-types C and
E exhibit enriched expression of genes associated with neuronal
differentiation and photoreceptor differentiation, respectively [8].
A fifth sub-type (D) was also identified, characterized by a mixed
signature of both neuronal and photoreceptor differentiation. Sub-
type specific gene expression signatures may ultimately prove
critical for the development of new targeted therapeutic agents as
well as the identification of subsets of patients responsive to specific
targeted therapies.
The identification of several molecular sub-types of MB suggests
that different sub-groups may arise from distinct cellsof origin. Indeed,
accumulating evidence from animal models suggests that some MB
sub-types arise from cerebellar granule cell precursors (GCPs),
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precursor cells of the dorsal brainstem [14]. In human MB,
a subpopulation of CD133-expressing cells was identified that
displayed similar properties to normal NSCs, including self-renewal
and multipotency [15,16]. Additional studies demonstrated that these
putative brain tumour stem cells (BTSCs) were capable of initiating
tumor formation in immunodeficient mice [17]. Engraftment of as few
as 100 CD133+ cells was sufficient for tumor formation, while as
many as 100 000 CD1332 cells failed to produce tumors. Taken
together, these findings in both humans and mice strongly implicate
normal CD133+ NSCs as candidate cells of origin for MB. While
mRNA expression profiling studies suggest that specific MB sub-types
may be derived from normal NSCs (Bertram et al,m a n u s c r i p ti n
preparation); the analysis of non-coding RNA expression represents
another approach to test this hypothesis. Integrated expression
profiling of both coding and non-coding RNAs will further
characterize the molecular sub-types of MB, and may give further
insight into MB pathogenesis and putative cells of origin.
microRNAs (miRNAs) are a class of short, non-coding RNAs
that post-transcriptionally down-regulate gene expression by
binding to the 39-untranslated region (UTR) of protein coding
transcripts, resulting in either mRNA cleavage or translational
repression [18,19]. At the time of writing, more than 1,000 human
miRNA genes have been identified (miRBase Release 16) [20] and
recent studies investigating miRNA target site conservation within
human 39UTRs suggest that expression of .60% of human
protein coding genes may be regulated by miRNAs [21]. An
individual miRNA may potentially bind and regulate many
different mRNA targets with related function, such as those
belonging to a single cell signaling pathway [22], whilst a given
mRNA target may be regulated by several different miRNAs,
creating a highly complex combinatorial network of gene
regulation [23]. miRNAs have important roles in the regulation
of diverse cellular processes including development, cell prolifer-
ation, apoptosis, differentiation and metabolism [24–28]. Not
surprisingly, abnormalities in miRNA expression and function
have been shown to affect these normal physiological processes,
with increasing evidence supporting a critical role for deregulated
miRNA expression in cancer initiation and progression [29,30].
We hypothesized that the identification of miRNA-regulated
networks of gene expression in human primary MB specimens,
relative to CD133+ NSCs, will improve our understanding of MB
pathogenesis. To date, several research groups have investigated
deregulated miRNA expression in MB [31–36], including
comparisons to normal human adult and fetal cerebellum
[33,34,36] which represent heterogeneous tissues at different
developmental stages. Our approach is distinct but complemen-
tary to these reports, and is the first to assess miRNA expression
levels in primary human MB specimens and MB cell lines in
comparison to human CD133+ NSCs and CD1332 neural
progenitor cells (NPCs). To identify candidate miRNA-regulated
networks of gene expression that may be involved in MB
pathogenesis, we then integrated these miRNA expression profiles
with mRNA gene expression data we obtained from the same
samples. Furthermore, we validated the regulation of a set of
predicted target genes by specific miRNAs in vitro. In summary,
our findings suggest that these miRNAs may have potential as
both therapeutic targets and clinical biomarkers of MB.
Methods
Ethics statement
Written approval to undertake this study was obtained from the
Princess Margaret Hospital (PMH) human ethics committee.
Written consent to use tumor material for research purposes was
obtained from the parents of patients according to PMH ethics
committee guidelines. All tumor material was de-identified to
ensure patient anonymity.
Patient samples
Primary brain tumors were collected at PMH, embedded in
optimal cutting temperature compound (OCT) and snap-frozen.
Ten MB specimens were analyzed. The age of patients ranged
from seven months to 13 years, with a mean age of 4.5 years.
Gender distribution was seven males to three females (2.3:1)
(Table 1).
Cell lines and neurosphere maintenance
The desmoplastic MB cell line PER547 and classic MB cell lines
PER 568 and PER 621 were established from primary specimens
[37] and cultured in RPMI supplemented with 20% fetal calf
serum at 37uC with 5% CO2. Primary MB specimens from which
these cell lines were derived were not included in the primary MB
cohort profiled in this study. Human NSCs propagated as
neurospheres were derived from human ESC lines hES3 (WiCell
Research Institute, Madison, WI, USA) and MEL1 (Australian
Stem Cell Centre, Melbourne, Australia) using protocols described
previously [38,39]. Neurospheres were maintained in neural basal
medium, supplemented with N2 (Gibco, Mt Waverley, Australia),
Penicillin/Streptomycin (Gibco, Mt Waverly, Australia), L-Gluta-
mine (Sigma, Castle Hill, Australia), Interferrin-Transferrin-
Selenium (Gibco, Mt Waverley, Australia), EGF (20 ng/ml,
Sigma, Castle Hill, Australia) and bFGF (20 ng/ml, Chemicon,
Melbourne, Australia). Neurosphere cultures were propagated by
mechanical splitting 1:2–1:4 [40] and cultured in ultra-low
adherent 96 well plates (Corning, Melbourne, Australia) with
growth factor supplementation every 2–3 days.
Neurosphere dissociation and CD133+ NSC isolation
Neurospheres were dissociated using the trypsin-neural dissoci-
ation kit (Miltenyi Biotec, North Ryde, Australia) as described
previously [41]. Dissociated NSC suspensions were washed and re-
suspended in FACS buffer (1xPBS supplemented with 0.5% BSA
(Sigma, Castle Hill, Australia) and 2 mM EDTA (Sigma, Castle
Table 1. Clinical data and methods used to profile miRNA
and mRNA expression.
Sample Gender Age M Status
miRNA
array
mRNA
gene array
M1 Female 9 M0 Yes No
M2 Female 3 Unknown Yes Yes
M6 Male 7 M+ Yes Yes
M7 Male 1.5 M0 Yes Yes
M9 Male 2 Unknown Yes No
M11 Male 5 M+ Yes Yes
M14 Female 3 M0 Yes Yes
M15 Male 3 M+ Yes Yes
M17 Male 4 M+ Yes Yes
M22 Male 1 Unknown Yes No
Metastatic status was defined as M0 (no metastasis) and M+ (distant
metastases).
doi:10.1371/journal.pone.0023935.t001
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North Ryde, Australia) for three min at room temperature and
CD133+ NSCs were isolated as described [41]. FACs enrichment
of CD1332 NPCs was 100% for both hES3 and MEL1 ESC lines,
with the enrichment of CD133+ NSCs 81.1% and 97% for the
hES3 and MEL1 ESC lines, respectively.
Small RNA isolation and enrichment
RNA enriched for small RNAs was isolated from primary
specimens, cell lines and NSC/NPCs using the miRNeasy mini kit
(Qiagen, Melbourne Australia), according to the manufacturer’s
protocol. Briefly, OCT compound was mechanically removed
from embedded frozen primary tumor specimens and tumor tissue
was placed in pre-weighed 1.5 ml eppendorf tubes containing
QIAzol reagent. For MB cell lines, up to 1610
7 cells were
harvested and pelleted by centrifugation for 5 min at 8000 rpm,
prior to RNA extraction. On-column DNase digestion was utilized
for all samples with RNase-free DNase (Qiagen, Melbourne,
Australia), according to manufacturer’s recommendations. RNA
quality was assessed by 1.5% agarose gel electrophoresis and
quantified on a Nanodrop 1000 (Biolab, Scoresby, Australia).
RNA quantity and purity was estimated by the ratio of absorbance
at 260 nm and 280 nm (OD260:OD280), with ratios between 1.8
and 2.0 being considered optimal.
miRNA expression profiling
miRNA profiling was performed using quantitative real-time
RT-PCR utilizing pre-printed Taqman low density assay (TLDA)
microfluidic cards (Human miR v2.0, Applied Biosystems,
Melbourne, Australia). Each TLDA card set contained MGB-
labeled probes specific to 762 mature miRNAs plus six
endogenous small nucleolar RNAs (MammU6, RNU44,
RNU48, RNU24, RNU43, RNU6B) for data normalization
and relative quantification. Briefly, reverse transcription was
performed with 30 ng small RNA enriched RNA using Megaplex
RT stem loop primer pools (Life Technologies, Melbourne),
Multiscribe Reverse Transcriptase (Life Technologies, Mel-
bourne), RNase inhibitor and100 nM deoxynucleotide triphos-
phates (dNTP). Two multiplex pools were used per sample, each
pool containing reagents and primers for 384 mature miRNAs
and small nucleolar RNAs. The multiplexed RT and Megaplex
pre-amplification reactions were performed according to manu-
facturer’s instructions. Pre-processing of raw TLDA data files
consisted of threshold and baseline corrections for each sample,
with each amplification plot assessed to confirm that the
threshold cycle (Ct) value corresponded with the midpoint of
logarithmic amplification (SDS 2.3, Life Technologies, Mel-
bourne). Ct values greater than 32 were imputed to 32 according
to the technical recommendation. Raw miRNA expression data is
available from the Telethon Institute for Child Health Research
(TICHR) webserver: http://bioinformatics.childhealthresearch.
org.au/datasets/.
Endogenous control (EC) gene normalization for miRNA
gene expression analysis
To determine the most appropriate combinations of genes for
data normalization, the expression stability and abundance of
candidate endogenous control genes were assessed using the
BestKeeper software program [42]. To assess the range of
expression levels of candidate EC genes, threshold cycle (Ct)
values for each were plotted across all samples (Figure S1).
Subsequently, Bestkeeper was employed to evaluate the expression
stability of several candidate EC genes, whilst simultaneously
assessing the best possible combination of EC gene pairs for
relative quantification of miRNA expression (Table S1). Ranking
of the candidates was performed based upon deviation of gene
expression, displayed as correlation of coefficient (r) to the
Bestkeeper Index (BI), defined as the geometric mean of all
candidate EC genes. Based on the abundance and stability of
candidate EC genes, MammU6 and RNU48 were selected for the
normalization of miRNA expression data, using the equation
2
2DCt, where DCt=(CtmiR2Ctmean endogenous control).
Statistics and Bioinformatics
All analyses were performed utilizing log2(2
2DCt) transformed
normalized miRNA expression data. Unsupervised agglomerative
hierarchical clustering of miRNA expression profiles was performed
using Euclidean distance and pairwise Pearson correlations with
complete linkage. Results were visualized using dendrograms and
heatmaps. All statistical analyses were performed in R statistical
environment version 2.9.2 [43]. Visualization of clustering analyses
was carried out using gplots R package (http://cran.r-project.org/
web/packages/gplots/index.html). Principle component analysis
(PCA) was performed using companion to applied regression (CAR)
package in R (http://cran.r-project.org/web/packages/car/index.
html). To identify specific miRNAs that were differentially
expressed between MB primary specimens, MB cell lines and
normal NSC/NPC samples, a two sample t-test was performed
utilizing the normalized means (log2(2
2DCt) of expression levels for
each miRNA in MB primary specimens, cell lines, CD133+ NSCs
and CD1332 NPCs. For CD133+ NSCs and CD1332 NPCs,
normalized means(log2(2
2DCt)ofexpression levels wereobtained by
averaging the expression of individual miRNAs from both hES3
and MEL1, therefore representing a pool of two ESC lines.
Significantly deregulated miRNAs were defined as those having
ap ,0.01 and a differential expression value .log2 fold change (FC)
of three (eight Cts). False discovery rate (FDR) corrected p-values
were also calculated. For comparison analyses, venn diagrams were
generated in R using limma package.
Integration of miRNA and mRNA expression data
The integration of miRNA and mRNA expression data was
performed using the online tool microRNA and mRNA integrated
analysis (MMIA) [44]. Multiple integration analyses were
performed, utilizing input lists including both significantly up-
and down-regulated miRNAs identified in primary MB specimens
from miRNA profiling analysis (Table S2). The miRNA target
prediction algorithm TargetScan 5.1 was employed for all analyses
[21,45,46], with miRNA and mRNA combined analysis per-
formed as previously described [47]. To refine miRNA-mRNA
target interactions, mRNA expression data were log2 transformed
and a mean two-fold cut-off (fch ,22, .2) for each target gene in
primary MB specimens was employed for mRNA data analysis.
Due to a limited sample size, we were unable to perform FDR
testing on the integration itself (as provided by MMIA). To limit
potential false positive findings, we utilized a strict t-test p-value
cutoff of ,0.01 in combination with a log2 differential expression
FC of greater than three for the deregulated miRNAs (when
compared to CD133+ NSCs). Only a subset of MB primary
specimens for which both miRNA and mRNA profiles were
available was included in these analyses (Table 1). Ingenuity
pathway analysis (IPA; Ingenuity Systems) was employed to assign
biological function to putative target genes of miRNAs with
significantly altered expression, utilizing candidate miRNA-
mRNA target gene pairs for which upon integration an inverse
correlation of expression was observed. IPA output was focused
miRNA Expression in Medulloblastoma
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significance.
Validation of miR-935 and miR-10a target gene
regulation in MB
Candidate miR-935 target genes obtained from MMIA
analyses, where miRNA and mRNA expression was inversely-
correlated, were ranked according to TargetScan context score,
with a context score greater than or equal to 20.4 subsequently
selected as the cut-off for validation in the laboratory. miR-935
expression levels were obtained using Taqman qRT-PCR miRNA
assay (Life Technologies) and correlated to selected putative target
gene levels using Pearson’s correlation. To validate selected
mRNAs as targets of a given miRNA, miRNAs were over-
expressed by transient transfection of synthetic precursor miRNAs
(pre-miRs) at 5 nmol/L (Life Technologies) in PER-547 cells and
30 nmol/L (Life Technologies) in PER-568 cells using Ribofect
transfection reagent (Bioline). Following small RNA-enriched
RNA extraction, significant up-regulation of miR-935 and miR-
10a was confirmed by qRT-PCR using two way analysis of
variance (ANOVA) and an unpaired t-test, respectively. Following
total RNA extraction (Qiazol), target mRNA gene expression
levels were measured by reverse transcriptase quantitative PCR
(qRT-PCR) at 24 hours post-transfection using Quantifast SYBR
Green Master Mix (Qiagen) with the primers: ACTB (59-CAT
GTA CGT TGC TAT CCA GGC -39 (forward) and 59- CTC
CTT AAT GTC ACG CAC GAT -39 (reverse); APC (59- CCT
CAT CCA GCT TTT ACA TGG C-39 (forward) and 59- CGC
CTG CCT CTC TTG TCA T-39 (reverse); KIAA0232 (59- CTG
CTG TCC AGT GTC TTC GAT-39 (forward) and 59- GGG
AGA CCC CTC TAA CTT TTT GT-39 (reverse); MYT1 (59-
GGA CGC CTC TGT TTC GGA TG-39 (forward) and 59- ATC
CAA AAT GGG ACT TGA CGG-39 (reverse); RELN (59- TCC
GGG ACA AGA ATA CCA TGT-39 (forward) and 59- CCA
AAT CCG AAA GCA CTG GAA-39 (reverse); SLC5A3 (59- CCC
AAT TTA CAT CCG GTC AGG-39 (forward) and 59- ATA
CAG ATC CAC CGA GAG CTT-39 (reverse); TBC1D9
(59- CCG TCA GGG TTG GAT GTA CC-39 (forward) and
59- GAA GAA ATG CTC ACT GGA CCG-39 (reverse) and
ZFAND6 (59- ACA GCC AAG TGC CTA TGC TTT-39
(forward) and 59- CAG ACA GAC TAC TGA CAG AGG T-39
(reverse). PIK3CA mRNA levels were normalized to b-actin
mRNA using Taqman assays on demand (Life Technologies),
according to manufacturer’s recommendations.
PIK3CA protein levels were analyzed by Western blotting at 48,
72 and 96 h post-transfection. The anti-pan actin and PI3 Kinase
p110a monoclonal antibodies were purchased from NeoMarkers
and Cell Signaling, respectively.
mRNA gene expression profiling
Total RNA was extracted from primary MB specimens, MB cell
lines, CD133+NSCs and CD1332 NPCs and subsequently
labelled and hybridized to Affymetrix HG-U133A arrays as
described previously [48]. Unsupervised hierarchical clustering
analysis was performed on the primary MB specimens, MB cell
lines, CD133+ NSCs, and CD1332 NPCs using the expression
levels of 20 of the 24 genes (LEF1, RUNX2, DCX, MAB21L1,
PTCH1, PDLIM3, NEUROG1, DLL3, PDGFA, FOXG1B,
GRM1, VAMP4, CDKN1C, SERPINF1, NRL, CRX,
NMNAT2, SMARCD3, GABRA5 and DCC) that classify MB
molecular subgroups A–E as defined by Kool et al [8]. The genes
OTX2, LEMD1, PTPN5 and ZNF179 were omitted from the
analysis because they are not represented on the Affymetrix
HG-U133A array.
Results
Global miRNA expression analyses of primary MB
specimens, MB cell lines and normal NSCs revealed four
distinct clusters
miRNA profiles were generated for primary MB specimens, MB
cell lines, CD133+ NSCs and CD1332 NPCs using qRT-PCR.
Unsupervised hierarchical clustering analysis of the 663 miRNAs
revealed distinctive expression patterns for MB primary speci-
mens, NSCs, NPCs and MB cell lines. The dendrogram included
two main branches representing four clusters of samples
(Figure 1A). Cluster one consisted of CD133+ NSC and
CD1332 NPC samples, which were distinct from both primary
specimens and MB cell lines. MB cell lines comprised cluster two,
with PER-547 separate to PER-568 and PER-621. Interestingly,
primary MB samples segregated into two distinct clusters (cluster
three and cluster four), suggesting two sub-types of primary MB
specimens based upon their miRNA profiles. Principal component
analysis (PCA) was applied to provide an additional method of
unsupervised visualization of miRNA expression profiles. This
revealed the same four clusters identified in the initial hierarchical
clustering (Figure 1B). Spatial separation of CD133+ NSCs and
CD1332 NPCs from MB primary specimens and cell lines was
evident. MB cell lines appeared as a separate cluster, with MB
primary samples segregated into two distinct groups. Additional
clustering analysis based on the 50 most significantly differentially
expressed miRNAs in both MB primary specimens and cell lines
compared to CD133+NSCs was consistent with these findings
(Figure 2) (For miRNA list see Table S2).
Up-regulation of miRNAs mapping to chromosomal
region 14q32 in MB
Paired t-tests were employed to identify differences in individual
miRNA expression levels between primary MB specimens and
normal CD133+ NSCs and CD1332 NPCs. Of the 663 miRNAs
included in the analysis, we identified 33 miRNAs (p,0.01) that
were significantly differentially expressed in primary MB samples
in comparison to CD133+ NSCs, including 21 of 33 (63.6%) that
were up-regulated and 12 of 33 (36.3%) that were down-regulated.
Lists of significantly up- and down- expressed miRNAs in MB
were generated on the basis of p-values for each miRNA (Table 2).
Interestingly, many of the up-regulated miRNAs mapped to
identical chromosomal regions. In particular, 10 of the 21 (47.6%)
up-regulated miRNAs mapped to chromosomal region 14q32
(Table 2). miRBase (Release 16) reported 58 miRNAs located at
14q32, thus 33.3% of miRNAs we have identified as deregulated
in MB map to this region (Fisher’s exact test, p,0.001). In
addition, four of the 21 (19%) up-regulated miRNAs were located
at chromosomal region 17q. A similar analysis was performed to
identify 53 differentially expressed miRNAs in MB versus
CD1332 NPCs, the majority of which were up-regulated in
MB (Table S3). Of these, 16/53 (30%) were also found to be
differentially expressed when compared to CD133+ NSCs
(Figure S2).
Integrative analysis of miRNA/mRNA expression identifies
several putative regulatory networks in MB
We performed MMIA to identify putative miRNA-regulated
networks in MB. Interestingly, these integrative analyses revealed
several miRNA mapping to 14q32 that were predicted to have
identical target genes. Of particular interest, up-regulated
miRNAs miR-494 and miR-495 were predicted to target
CTNND2, while up-regulated miR-376c and miR-409-3p were
miRNA Expression in Medulloblastoma
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primary MB specimens relative to CD133+ NSCs (Table S4).
To address the functional significance of the putative targets of
differentially expressed miRNAs, IPA enrichment analysis was
performed focusing on dysregulated mRNA targets of both the up-
and down-regulated miRNAs identified as differentially expressed
in MB (Table S4 and Table S5, respectively). The top 30 enriched
pathways in primary MB specimens relative to CD133+ NSCs and
CD1332 NPCs are listed in Table S6 and Table S7, respectively.
Functional enrichment analyses of negatively-correlated targets of
both up- and down-regulated miRNAs revealed 106 significant
pathways (Fisher’s exact test, p,0.05). This included over-
representation of pathways associated with neuronal migration
and nervous system development, such as Axonal Guidance
(p,0.0001) and Reelin Signaling in Neurons (p,0.0001) (Table 3),
and pathways related to cell proliferation and programmed cell
death including the Insulin growth factor 1 (IGF1) (p=0.0002)
and Phosphatase and tensin homolog (PTEN) pathways
(p=0.0005) (Table 3). Common miRNA target genes of these
over-represented pathways included both Phosphoinositide-3-
kinase, catalytic alpha polypeptide (PIK3CA) and the related
Phosphoinositide-3-kinase, regulatory subunit 1 (PIK3R1) featuring
in 77 of the 106 (72.6%) significant pathways. Similarly,
Adenomatosis polyposis coli (APC) featured in 12 of the 106
(11.3%) signaling pathways. Thus, pathway analysis suggested
deregulated miRNA-regulated networks of gene expression in MB
affect both developmental signaling and the regulation of cell
proliferation.
Validation of putative miR-935 and miR-10a targets in MB
To evaluate the robustness of miRNA/mRNA predictions
identified by the integration of miRNA and mRNA expression
data and to gain insight into the potential role of differentially
expressed miRNAs in MB, we first focused on the most
Figure 1. Clustering analysis of primary MB, MB cell lines and CD133+ NSCs and CD1332 NPCs. (A) Unsupervised hierarchical
clustering and (B) PCA. The analyses were based on normalized expression data for 662 miRNAs in ten primary MB specimens, three MB cell lines
(PER-547, PER-568 and PER-621), two CD133+ NSC and two CD1332 NPC samples. Sample numbers refer to those in Table 1. The similarity metric
utilized for unsupervised hierarchical clustering was Pearson’s correlation (r). MB sub-typing determined from mRNA gene expression analysis is
indicated. Sub-type B is characterized by over-active SHH signaling, whilst sub-type C is characterized by the enriched expression of genes associated
with neuronal differentiation. Sub-type E is characterized by enriched expression of photoreceptor genes, whilst sub-type D is characterized by mixed
neuronal and photoreceptor genes. Primary MB specimens defined as ‘‘NA’’ were not available for sub-typing analysis. The M1 primary sample failed
on the Pool B TLDA card and was therefore excluded from PCA, as this type of analysis cannot be performed on incomplete datasets. Primary MB
sample, M15, grouped with cluster three, as compared to cluster four in Figure 1A.
doi:10.1371/journal.pone.0023935.g001
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miR-935 targets predicted by TargetScan were up-regulated in
MB compared to CD133+ NSCs (Table S5). Among these were
genes with established roles in neuronal migration, cell adhesion
and the development of the CNS including Reelin (RELN) and
Myelin transcription factor 1 (MYT1). We ranked up-regulated
predicted target genes on the basis of Targetscan context score and
selected the top six candidates for functional testing, in addition to
APC due to its presence in multiple enriched pathways. To assess
whether putative miRNA target genes had inverse expression to
miR-935 levels in MB, we correlated expression levels of miR-935
with selected target genes in MB primary specimens. A moderate
to strong negative correlation was observed for the majority of
miR-935 target genes, supporting prediction and integration
analyses (Table 4).
To address whether miR-935 regulates predicted target genes
in MB, transient over-expression of miR-935 in the MB cell line,
PER-547, which has 7000 fold decreased levels of miR-935
relative to normal CD133+ NSCs, was performed. Significant up-
regulation of miR-935 was confirmed by qRT-PCR, with
,11 000 fold up-regulation of miR-935 in pre-miR-935
transfected cells at 24 h compared to scrambled negative control
cells (p,0.01). Significant down-regulation of three of the seven
predicted miR-935 target genes was observed at the mRNA level
Figure 2. Heatmap analysis based on deregulated miRNAs in MB primary specimens and cell lines compared to CD133+ NSCs.
Sample numbers refer to those in Table 1. The similarity metric utilized for this analysis was log2(2
2DCt) transformed miRNA values obtained from
qRT-PCR profiling analysis. miRNA expression in normal CD133+ NSCs was determined from averaging log2(2
2DCt) transformed miRNA values of
CD133+ NSCs from both hES3 and MEL1 ESC lines. A red to green color scale (220 to +2) depicts normalized miRNA expression on a log scale, with
median expression across all samples represented as black. White spaces in the heatmap are due to M1 primary sample failing on Pool B TLDA card.
doi:10.1371/journal.pone.0023935.g002
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(p=0.0251), Hypothetical protein LOC9778 (KIAA0232)
(p=0.0004) and Zinc Finger AN1-type domain 6 (ZFAND6)
(p=0.0037). Furthermore, down-regulation of TBC domain
family member 9 (TBC1D9) approached statistical significance
(p=0.064). Expression levels of APC, RELN and MYT1 remained
unchanged at the mRNA level following transfection (data not
shown), although it is possible that miR-935 could regulate
expression of APC, RELN and MYT1 at the translational level.
Following this, we investigated the potential regulation of PIK3CA
by miR-10a, given the over-representation of this gene in the
majority of enriched signaling pathways. Transient over-expres-
sion of miR-10a in the MB cell lines, PER-547 and PER-568 was
performed, which has 125 fold and 2200 fold decreased levels of
miR-10a relative to normal CD133+ NSCs, respectively.
Significant up-regulation of miR-10a was confirmed by qRT-
PCR, with ,40 000 fold (p=0.005) up-regulation of miR-10a in
pre-miR-10a transfected PER-547 and ,200 000 fold up-
regulation in PER-568 cells at 24 h, compared to scrambled
negative control cells. However, transient over-expression of
miR-10a in both MB cell lines, PER-547 and PER-568, did not
affect PIK3CA mRNA or protein levels (data not shown).
Nevertheless, our results with mir-935 target genes indicated that
the integration of miRNA and mRNA expression data was
a useful approach for the identification of putative miRNA-
regulated genes in MB.
Table 2. Significantly up- and down-regulated miRNAs in primary MB specimens relative to CD133+ NSCs.
miRNA Chromosomal location p value FDR adjusted p value Fold Change (log2)
UP-REGULATED
hsa-miR-127-3p 14q32.2 0.0001 0.0071 6.33
hsa-miR-539 14q32.31 ,0.0001 0.0031 5.91
hsa-miR-495 14q32.31 ,0.0001 0.0031 6.00
hsa-miR-409-3p 14q32.31 0.0001 0.0058 7.10
hsa-miR-494 14q32.31 0.0012 0.0316 3.80
hsa-miR-376c 14q32.31 0.0014 0.0341 6.39
hsa-miR-379 14q32.31 0.0019 0.0400 4.90
hsa-miR-376a 14q32.31 0.0073 0.1209 5.04
hsa-miR-323-3p 14q32.31 0.0077 0.1248 3.45
hsa-miR-203 14q32.33 0.0004 0.0132 5.96
hsa-miR-193a-5p 17q11.2 0.0001 0.0048 3.93
hsa-miR-144* 17q11.2 0.0069 0.1167 6.12
hsa-miR-21* 17q23.1 0.0025 0.0509 3.67
hsa-miR-338-3p 17q25.3 0.0043 0.0807 3.36
hsa-miR-143 5q32 ,0.0001 0.0010 6.06
hsa-miR-145 5q32 0.0016 0.0359 3.67
hsa-miR-146a 5q34 ,0.0001 0.0010 7.57
hsa-miR-126 9q34.3 ,0.0001 0.0005 6.28
hsa-miR-126* 9q34.3 ,0.0001 0.0005 6.61
hsa-miR-223 Xq12 0.0052 0.0906 11.16
hsa-miR-361-3p Xq21.2 0.0009 0.0236 3.06
DOWN-REGULATED
hsa-miR-483-5p 11p15.5 0.0091 0.1408 24.91
hsa-miR-10a 17q21.32 0.0007 0.0219 25.19
hsa-miR-373 19q13.42 ,0.0001 0.0031 23.74
hsa-miR-935 19q13.42 0.0002 0.0082 28.37
hsa-miR-92b* 1q22 0.0050 0.0888 24.32
hsa-miR-302b* 4q25 0.0005 0.0153 23.84
hsa-miR-302d* 4q25 0.0049 0.0888 24.11
hsa-miR-219-1-3p 6p21.32 0.0002 0.0082 24.86
hsa-miR-219-5p 6p21.32/9q34.11 0.0008 0.0236 24.93
hsa-miR-219-2-3p 9q34.11 0.0003 0.0127 27.12
hsa-miR-106a* Xq26.2 0.0100 0.1507 23.98
hsa-miR-504 Xq26.3 0.0003 0.0106 25.02
miRNAs are sorted according to their chromosomal location. miRNA expression in normal CD133+ NSCs was determined from averaging log2(2
2DCt) transformed miRNA
values of CD133+ NSCs from both hES3 and MEL1 ESC lines.
doi:10.1371/journal.pone.0023935.t002
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The precise cell of origin for MB remains to be determined,
however data from both human and mice studies suggest that some
MB sub-types arise from NSCs [11–13,15–17]. Several research
groups have investigated deregulated miRNA expression in MB
pathogenesis and have evaluated miRNA expression levels relative
to normalhumancerebellum.However,normalcerebellum consists
of a heterogenous population ofcell types and maynotrepresentthe
optimal normal control tissue [33,34,36]. This is the first study to
perform global miRNA profiling of human MB primary specimens
relative to a putative cell of origin, CD133+ NSCs.
miRNA profiling has been used previously to classify tumors
according to their molecular and histological sub-type [49–51]. In
this study, clustering analysis based on miRNA expression
profiling identified two distinct sub-groups of primary MB
specimens, a finding reminiscent of sub-types identified on the
basis of mRNA expression profiles. Primary MB specimens in
cluster three represented Shh-driven sub-type B, whilst specimens
in cluster four represented sub-types C, D and E (Bertram et al.,
manuscript in preparation and [8]). Additionally, our clustering
analysis based on miRNA expression profiling revealed MB cell
lines clustering as a distinct subgroup from primary MB
specimens. This is consistent with previous reports in bladder
cancer [52], cholangiocarcinoma [53] and germ cell tumors [54]
highlighting underlying differences in miRNA expression between
immortalized cell lines grown in culture and primary tumor
specimens, in addition to sample heterogeneity due to the absence
of stroma in cell lines. Although based on small sample sizes, our
findings suggest that miRNA expression profiling is capable of
classifying primary MB specimens into different tumor sub-groups.
Larger sample numbers are required to further characterize these
sub-groups at the miRNA level.
The majority of differentially expressed miRNAs in MB were
up-regulated in comparison to normal CD133+ NSCs. This is in
contrast to previous reports of general down-regulation of miRNA
gene expression in primary human MB compared to normal adult
and fetal cerebellum [33,34,36]. A possible explanation for this
discrepancy lies with the varying differentiation status of each of
the normal populations used for comparison. Accumulating
evidence indicates that miRNA expression profiles reflect the
state of cellular differentiation, due to the critical role of miRNAs
in the regulation of the terminal differentiation of numerous cell
types [24,30,55,56]. Consistent with this, miRNA profiling studies
performed in embryonic stem cells, embryoid bodies and day 11
mouse embryos indicated that both miRNA expression levels and
the number of different miRNAs expressed increased as the
maturation process progressed towards terminal differentiation
[57]. Furthermore, recent studies have indicated that normal
human adult cerebellum has higher expression levels of miRNAs
when compared to pediatric cerebellum, consistent with develop-
mentally regulated temporal expression of miRNAs in the brain
[36]. Therefore, we suggest that the over-expression of miRNAs in
MB observed in this study reflects our comparison of miRNA
levels in MB to multipotent NSCs.
Table 3. Pathway enrichment analysis of putative mRNA targets of deregulated miRNAs in primary MB specimens versus CD133+
NSCs using IPA pathway curated gene sets.
Ingenuity Canonical Pathways p value Genes
Molecular Mechanisms of Cancer ,0.0001 NF1, PIK3R1, APC, ARHGEF3, WNT5A, PRKAR2A, PRKD1, NOTCH1, SMAD3,
PIK3CA, TCF3, CCND2, SMAD2, RALGDS, FZD7, ARHGEF12, TGFBR2, RRAS2,
RAP2A, PRKACB, NRAS, CDC25A, MAPK10
Colorectal Cancer Metastasis Signaling ,0.0001 PIK3R1, APC, WNT5A, PRKAR2A, SMAD3, PIK3CA, TCF3, SMAD2, RALGDS, MSH6,
FZD7, TGFBR2, RRAS2, PRKACB, NRAS, GNB5, BIRC5, MAPK10
Ovarian Cancer Signaling ,0.0001 PIK3R1, APC, FZD7, RRAS2, WNT5A, PRKAR2A, TCF3, PIK3CA, NRAS, PRKACB, CD44, MSH6
Reelin Signaling in Neurons ,0.0001 PIK3R1, ARHGEF12, ARHGEF3, ITGA6, PIK3CA, RELN, DCX, ARHGEF9, MAPK10
Axonal Guidance Signaling ,0.0001 PIK3R1, GLI3, WNT5A, PRKAR2A, PRKD1, PIK3CA, WASL (includes EG:8976), EPHA3,
SEMA5A, NFATC1, FZD7, EFNB3, ARHGEF12, RRAS2, NFAT5, EPHB2, PRKACB, NRAS,
GNB5, NTRK2, SHANK2
IGF-1 Signaling 0.0002 PIK3R1, RRAS2, PRKAR2A, PIK3CA, GRB10, NRAS, PRKACB, FOXO3, CYR61
Human Embryonic Stem Cell Pluripotency 0.0002 PIK3R1, APC, FZD7, FGFR2, TGFBR2, WNT5A, SMAD3, TCF3, PIK3CA, SMAD2, NTRK2
PPARa/RXRa Activation 0.0003 NCOR2, RRAS2, TGFBR2, PRKAR2A, MED1, SMAD3, NRAS, PRKACB, MAP4K4, SMAD2,
ACOX1, GHR
Regulation of IL-2 Expression in Activated
and Anergic T Lymphocytes
0.0003 NFATC1, RRAS2, TGFBR2, NFAT5, SMAD3, NRAS, SMAD2, MAPK10
PTEN Signaling 0.0005 PIK3R1, FGFR2, RRAS2, TGFBR2, PIK3CA, NRAS, FOXO3, NTRK2, GHR
The top ten enrichment terms are listed and were sorted based on statistical significance.
doi:10.1371/journal.pone.0023935.t003
Table 4. Pearson’s correlation analysis between miR-935
relative expression levels and expression levels of selected
target genes.
Target Gene Pearson’s value (r) p-value
APC 0.04 0.4597
KIAA0232 20.23 0.3196
MYT1 0.84 0.0096
RELN 20.39 0.1886
SLC5A3 20.66 0.0527
TBC1D9 20.35 0.2219
ZFAND6 20.55 0.0985
Pearson’s correlation (r) indicates a moderate to strong negative correlation
value for majority of target genes.
doi:10.1371/journal.pone.0023935.t004
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known miRNA genes residing in clusters of two or more separated
by less than 5000 nucleotides [58,59]. We found multiple miRNAs
with significantly altered expression in MB mapped to identical
chromosomal regions, including 14q32, which contains one of the
largest known bipartite miRNA clusters in vertebrates, consisting
of 47 miRNA genes in total [20,60]. Previous studies reported that
miRNAs mapping to this region are transcribed as a long
polycistronic transcript, spanning approximately 210 kb of the
mouse genome [60,61]. Evolutionary conservation of clustered
miRNA genes suggests an important common biological function,
with clustered miRNAs shown to co-regulate identical targets or
other components of the same pathway [62,63]. Consistent with
this, we identified several miRNAs mapping to 14q32 that were
predicted to target the same down-regulated target genes. Thus,
the identification of aberrantly expressed miRNA genes clustered
in identical chromosomal locations suggests they may have
a critical role in the coordinate regulation of target gene expression
in MB.
Up-regulation of miRNAs mapping to 14q32 has been reported
in other cancers including acute myeloid leukemia [64] and
gastrointestinal stromal tumors [65]. Additionally, findings ob-
tained in this study are consistent with those described by
Northcott et al (2009) [33], where the up-regulation of several
miRNAs mapping to 14q32 was observed in metastatic MB
specimens with a neuronal differentiation signature. Given that
a subset of primary MB specimens utilized in this study shared this
signature, this suggests that the up-regulation of miRNAs mapping
to 14q32 may be representative of metastatic disease. Despite this,
the precise function of miRNAs mapping to 14q32 has not been
elucidated. Expression of several miRNAs mapping to this region
has been demonstrated throughout embryonic development in
mice, progressively decreasing during postnatal development and
ultimately becoming restricted to the adult brain [60,61]. Gene
ontology (GO) enrichment analysis performed on predicted targets
of these miRNAs pointed to their roles in neurogenesis, cell
motility and nervous system development [66]. Moreover, several
genes of the MAPK signaling pathway predicted to be targeted by
miRNAs mapping to 14q32 have been previously shown to be
aberrantly expressed in Group C and D MB primary specimens
[8]; for instance, the MAPK signaling genes, FGF13, MAPK10 and
FGFR2, were down-regulated in primary MB specimens. Thus,
our findings suggest that the up-regulation of miRNAs mapping to
14q32 in MB may regulate signaling pathways that have
previously implicated in MB pathogenesis.
Enrichment analysis of predicted mRNA targets of the miRNAs
that were aberrantly expressed in MB identified several pathways
of interest in MB pathogenesis including neuronal development
Figure 3. Validation of putative miR-935 targets in PER-547 cells. Quantitative RT-PCR analysis of (A) KIAA0232 (B) SLC5A3 (C) TBC1D9 and (D)
ZFAND6 expression levels in PER-547 cells 24 h after transfection with scrambled negative control or pre-miR-935. Target gene expression levels in
pre-miR-935-transfected samples were normalized to scrambled control levels. p values were obtained from a two way ANOVA on log transformed
expression data. Error bars represent mean +/2 SEM from six independent experiments.
doi:10.1371/journal.pone.0023935.g003
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Axonal guidance signaling has been shown to regulate both
neuronal migration and survival [67], with several studies
identifying aberrant expression of this signaling pathway in
a variety of different human tumor types (Reviewed in [68]).
Similarly, Reelin signaling has been shown to play a critical role
during embryonic brain development in the positioning and
migration of Purkinje cells and subsequent expansion of granule
cell precursors (GCPs) during early cerebellum development
[69,70]. Transgenic mouse studies have also indicated a role for
Reelin in NSC proliferation, where an absence of RELN
expression results in decreased NSC proliferation [71] and
migration [71,72]. IPA highlighted several putative miRNA-
regulated signaling pathways containing the genes PIK3CA and
PIK3R1 as prominent in MB. Hyperactivation of Phosphoinositide
3-kinase (PI3K) signaling in several types of human cancers
including MB is widely reported [73,74], resulting in increased
activity of the downstream effector Akt [75]. In turn, this promotes
cancer cell growth [76,77], invasion [78] and apoptosis resistance
[79,80] and thus PI3K and Akt have emerged as key targets for the
development of novel anti-cancer therapeutics [81,82]. PIK3CA
expression is reportedly up-regulated in primary MB [83], and
PI3K signaling is critical to normal GCP and MB cell proliferation
[74,83,84]. Moreover, activation of PI3K signaling is essential for
the proliferation of MB BTSCs residing in the perivascular niche
following irradiation [85], suggesting that its targeted inhibition
might impair the tumor resistance to radiation therapy. Thus, our
findings suggest that the aberrant expression of miRNAs in MB
may be involved in the regulation of critical pathways involved in
embryonic and neuronal development, in addition to cell
proliferation pathways previously linked to MB pathogenesis.
Integrative analysis of miRNA and mRNA gene expression is
a robust and valuable approach for the identification of
computationally predicted target genes in MB. Computational
prediction of ‘‘true’’ miRNA targets is challenging, largely due to
the context-dependent nature of post-transcriptional regulation
resulting in a significant proportion of false-positive predicted
miRNA/mRNA interactions [45,86]. The approach taken in our
study aimed to reduce the proportion of false-positive predictions,
by integrating target gene predictions with gene expression profiles
to select for inversely-correlated, functional miRNA/mRNA
relationships. Whilst little is known about the role of miR-935-
regulated target genes KIAA0232 and ZFAND6, SLC5A3 plays an
important role in mammalian osmoregulation [87]. SLC5A3 is
a widely expressed sodium/myo-inositol (MI) co-transporter,
functioning to maintain intracellular MI levels [88]. Alterations in
MIlevelshave beensuggestedto affectphosphatidylinositol synthesis
[89], with altered levels of Phosphatidylinositol 3-phosphate (PI3P)
and Phosphatidylinositol-4,5-bisphosphate (PIP2)p o s s i b l yl i n k e dt o
aberrant PI3K signaling [90]. Taken together, experimental
validation of several miR-935 regulated target genes in MB cells
confirmed the validity of this approach, suggesting that predicted
miRNA/mRNA interactions obtained in our study may represent
functional miRNA/mRNA networks in MB.
A comparison of previously published MB miRNA expression
datasets reveals significant differences with respect to expression
patterns of individual miRNAs. Previous studies compared
miRNA expression in primary MB specimens to both adult and
fetal normal human cerebellum, with discrepancies likely due to
varied source and age of the cerebellum used for comparison as
previously discussed [36]. Not surprisingly, deregulated miRNAs
identified in our study differ from those previously identified as
deregulated in MB, likely due to our comparison to normal control
reference CD133+ NSCs. More specifically, comparison of the
available miRNA data sets relative to adult and fetal human
cerebellum with our data identified no significantly deregulated
miRNAs as overlapping between the three studies (Figure S3).
Additionally, miRNA expression levels in different studies were
obtained using varied profiling platforms, previously identified as
a source of miRNA expression variation in other reports [91].
Despite this, the identification of deregulated miRNAs specific to
individual MB sub-types, as performed by Northcott et al (2009)
[33], revealed comparable findings to those obtained in this study.
In particular, several miRNAs mapping to 14q32, including miR-
376c, miR-495 and miR-539, were identified as up-regulated in
MB specimens defined by a neuronal differentiation signature
(sub-type C as per [8]) [33]. This is consistent with our findings in
which the majority of MB specimens were also characterized by
either the neuronal differentiation (sub-type C) or mixed neuronal
and photoreceptor gene signatures (sub-type DE). In addition, two
miRNAs of the miR-106/-363 cluster mapping to chromosomal
region Xq26.2 were specifically down-regulated in tumours
characterized by a neuronal differentiation signature [33],
consistent with the down-regulation of Xq26.2 miRNA, miR-
106a* observed in this study. Therefore, future MB miRNA
profiling studies should take into account potential inconsistencies
between dataset comparisons due to both the platforms used and
the source of normal reference RNA.
In summary, using an integrative approach we have identified
aberrant miRNA-regulated networks that may be involved in the
transformation of normal NSCs to BTSCs. These data provide
a platform for future investigations aimed at characterizing the
functional significance of these networks in MB pathogenesis.
Supporting Information
Figure S1 Range of Ct values of EC reference genes
across all samples. MammU6 and RNU48 are the most
abundantly expressed EC reference genes. All samples were
included in this analysis except for one primary MB sample, due to
this sample failing with Pool B TLDA card.
(EPS)
Figure S2 Overlap of deregulated miRNAs in primary
MB specimens when compared to both CD133+ NSCs
and CD1332 NPCs. miRNA expression in normal CD133+
NSCs/CD1332 NPCs was determined from averaging
log2(2
2DCt) transformed miRNA values of CD133+ NSCs/
CD1332 NPCs from both hES3 and MEL1 ESC lines.
(EPS)
Figure S3 Comparison analyses of deregulated miRNAs
identified in primary MB specimens relative to previ-
ously published studies of Ferretti et al., (2009) and
Northcott et al. (2009). Venn diagrams were constructed
containing significantly differentially expressed miRNAs identified
in primary specimens relative to CD133+ NSCs from this study
and all deregulated miRNAs (p,0.05) in primary MB specimens
relative to (A) both adult and fetal human cerebellum and (B)
human fetal cerebellum alone.
(EPS)
Table S1 Repeated pair-wise correlation analysis be-
tween Endogenous control (EC) genes and Bestkeeper
Index (BI). Highest ranked correlations for RNU6B (r=0.897),
MammU6 (r=0.866), RNU43 (r=0.792) and RNU48 (r=0.723).
Three candidate pairs of EC genes were identified with similar
levels of correlation to each other and to BI, including RNU6B/
RNU43, MammU6/RNU48 and RNU48/RNU24.
(DOC)
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in primary MB specimens and/or MB cell lines relative
to CD133+ NSCs. miRNAs sorted according to their chromo-
somal location. miRNA expression in normal CD133+ NSCs was
determined from averaging log2(2
2DCt) transformed miRNA
values of CD133+ NSCs from both hES3 and MEL1 ESC lines.
(DOC)
Table S3 Significantly up- and down-regulated miRNAs in
primary MB specimens relative to CD1332 NPCs. miRNAs
are sorted according to their chromosomal location. miRNA expres-
sion in normal CD133+ NSCs was determined from averaging
log2(2
2DCt) transformed miRNA values of CD133+ NSCs from both
hES3 and MEL1 ESC lines.
(DOC)
Table S4 Down-regulated putative mRNA target genes
of up-regulated miRNAs in MB. All predicted miRNA target
genes listed in the table were down-regulated in primary MB
specimens, relative to CD133+ NSCs. All target genes listed were
included in IPA pathway enrichment analysis.
(DOC)
Table S5 Up-regulated putative mRNA target genes of
down-regulated miRNAs in MB. All predicted miRNA target
genes listed in the table were up-regulated in primary MB
specimens, relative to CD133+ NSCs. All target genes listed were
included in IPA pathway enrichment analysis.
(DOC)
Table S6 Enrichment analysis of the top 30 IPA pathway
curated gene sets using putative mRNA target genes of
up-regulated and down-regulated miRNAs in primary
MB specimens relative to CD133+ NSCs.
(DOC)
Table S7 Enrichment analysis of the top 30 IPA pathway
curated gene sets using putative mRNA target genes of
up-regulated and down-regulated miRNAs in primary
MB specimens relative to CD1332 NPCs.
(DOC)
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